electroCore

electroCore Provides Update on COVID-19 Clinical Initiatives | Globe Newswire | 4/27/2020

… Treat Respiratory Symptoms Associated with COVID-19: A Theoretical Hypothesis and Early Clinical Experience,” accepted for publication in the journal Neuromodulation: Technology at the Neural Interface BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) – electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on ongoing nVNS COVID-19 initiatives. The company announced today that an investigator-initiated, randomized, controlled clinical trial of nVNS therapy has …

electroCore Provides Business Update and Select First Quarter 2020 Guidance Nasdaq:ECOR | Globe Newswire | 4/17/2020

BASKING RIDGE, N.J., electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus nerve …

Follow electroCore:    

electroCore Provides Business Update and Select First Quarter 2020 Guidance Nasdaq:ECOR | Globe Newswire | 4/17/2020

BASKING RIDGE, N.J., electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus nerve …

electroCore Provides Business Update and Select First Quarter 2020 Guidance Nasdaq:ECOR | Globe Newswire | 4/17/2020

BASKING RIDGE, N.J., electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus nerve …

electroCore Provides Business Update and Select First Quarter 2020 Guidance Nasdaq:ECOR | Globe Newswire | 4/17/2020

BASKING RIDGE, N.J., electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus nerve …

Comparing BioSig Technologies (NASDAQ:BSGM) & electroCore (NASDAQ:ECOR) | 4/12/2020

… designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California. Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for electroCore and related companies with MarketBeat.com’s FREE daily email newsletter …

Analyzing electroCore (NASDAQ:ECOR) and BioSig Technologies (NASDAQ:BSGM) - American Banking News | 4/11/2020

… tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California. About electroCore electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company …

electroCore (NASDAQ:ECOR) Shares Gap Down to $0.86 - Ticker Report | 4/10/2020

electroCore, Inc. (NASDAQ:ECOR)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $0.82, but opened at $0.86. electroCore shares last traded at $0.80, with a volume of 24,165 shares changing hands. A number of research analysts recently weighed in on ECOR shares. HC Wainwright lowered their price objective on shares of electroCore from $2.00 to $1.50 and set a “buy” rating …

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K. | Benzinga | 4/9/2020

BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) – electroCore , Inc. (NASDAQ: ECOR ), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore in the treatment of cluster headache in adults. The extension will run through September 2020 and via this program, which started in April 2019, gammaCore will …

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K. | Globe Newswire | 4/8/2020

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K. ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 April 08, 2020 16:01 ET Source: electroCore , Inc. BASKING RIDGE, N.J., April 08, electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the …

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 | 4/8/2020

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 Published: Apr 08, 2020 BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) – electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and …

electroCore, Inc. Announces Extension of NHS Englands Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore in the U.K. | Financial Buzz | 4/8/2020

BASKING RIDGE, N.J., electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore in the treatment of cluster headache in adults. The extension will run through September 2020 and via this program, which started in April 2019, gammaCore will continue to be reimbursed for …

74 Biggest Movers From Friday | Benzinga | 4/6/2020

… telebriefing on development updates regarding vicromaxa novel broad-spectrum anti-viral candidate that ‘may treat COVID-19’ on April 7. Super League Gaming, Inc. (NASDAQ: SLGG ) jumped 42% to close at $2.94 on Friday. electroCore , Inc. (NASDAQ: ECOR ) shares surged 38% to close at $1.03 on Friday after the company announced it has submitted an Emergency Use Authorization application to the FDA to allow the study and use of gammaCore …

Today’s New Buy Pick - electroCore, Inc. (ECOR) – Buy Target – $1.10 or better | 4/6/2020

… safety first and foremost. At the same time, it’s worth taking note of the very real impact the widespread shut down of business activity is having. Last week’s unemployment cla… Read More Featured Stock electroCore, Inc. (ECOR) – Buy Target – $1.10 or better electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in …

electroCore (NASDAQ:ECOR) Sees Strong Trading Volume | 4/5/2020

… of 1,193,521 shares.The stock last traded at $1.03 and had previously closed at $0.75. ECOR has been the topic of a number of analyst reports. Cantor Fitzgerald cut their price target on shares of electroCore from $4.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 24th. Noble Financial restated a “buy” rating and set a $4.00 target price on shares of …

electroCore (NASDAQ:ECOR) Shares Down 21.5% | 4/3/2020

… the average session volume of 551,534 shares. The stock had previously closed at $1.21. A number of research analysts recently issued reports on the stock. Cantor Fitzgerald decreased their target price on shares of electroCore from $4.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, March 24th. Zacks Investment Research upgraded shares of electroCore from a “hold” rating to a “buy” rating …

electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19 | BioSpace | 4/3/2020

BASKING RIDGE, N.J., April 02, 2020 (GLOBE NEWSWIRE) – electroCore , Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate the study and clinical use of its gammaCore Sapphire TM non-invasive vagus nerve stimulation therapy, or nVNS, for respiratory symptoms associated with COVID-19 . The EUA includes data …

electroCore, Inc. (NASDAQ:ECOR) Short Interest Update - Ticker Report | 4/3/2020

… volume of 232,900 shares, the short-interest ratio is currently 6.2 days. Institutional investors have recently added to or reduced their stakes in the stock. Oxford Asset Management LLP purchased a new stake in electroCore during the fourth quarter valued at $29,000. Tobias Financial Advisors Inc. purchased a new stake in electroCore during the fourth quarter valued at $41,000. Bank of New York Mellon Corp raised its stake in electroCore

25 Stocks Moving in Friday’s Pre-Market Session | Benzinga | 4/3/2020

Gainers electroCore , Inc. (NASDAQ: ECOR ) shares rose 83.5% to $1.37 in pre-market trading after the company submitted emergency use authorization application to allow study and use of gammaCore nVNS therapy to treat respiratory symptoms associated with coronavirus. Fate Therapeutics Inc (NASDAQ: FATE ) rose 23.4% to $26.00 in pre-market trading after the company announced the first patient has been treated in its first-in-human Phase 1 clinical trial …

17 Healthcare Stocks Moving In Friday’s Pre-Market Session | Benzinga | 4/3/2020

Gainers • electroCore , Inc. (NASDAQ: ECOR ) shares rose 108.98% to $1.56 during Friday’s pre-market session. The most recent rating by H.C. Wainwright, on Mar 24, is at Buy, with a price target of $2. • Fate Therapeutics, Inc. (NASDAQ: FATE ) stock increased by 21.21% to $25.54. The most recent rating by Citigroup, on Mar 4, is at Buy, with a price target of $41. • Athersys, Inc. (NASDAQ: ATHX ) shares increased by …

Oxford Asset Management LLP Acquires Shares of 18,446 electroCore, Inc. (NASDAQ:ECOR) - Dakota Financial News | 4/3/2020

Oxford Asset Management LLP bought a new position in electroCore, Inc. (NASDAQ:ECOR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,446 shares of the company’s stock, valued at approximately $29,000. Oxford Asset Management LLP owned approximately 0.06% of electroCore as of its most recent filing with the Securities & Exchange Commission. Separately, Tobias Financial Advisors …

Thinking about buying stock in Capricor Therapeutics, Chesapeake Energy Corp, electroCore, General Motors, or MGM Resorts? | PR Newswire | 4/3/2020

NEW YORK , April InvestorsObserver issues critical PriceWatch Alerts for CAPR, CHK, ECOR, GM, and MGM. To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link. CAPR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CAPR&prnumber=040320200 CHK: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CHK&prnumber=040320200 ECOR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ECOR&prnumber …

electroCore (NASDAQ:ECOR) Shares Gap Down to $0.95 | Daily Political | 4/3/2020

electroCore, Inc. (NASDAQ:ECOR)’s stock price gapped down prior to trading on Wednesday . $0.96, but opened at $0.95. electroCore shares last traded at $0.78, with a volume of 1,010,070 shares traded. A number of equities research analysts have weighed in on ECOR shares. Cantor Fitzgerald lowered their price target on electroCore from $4.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, March …

ElectroCore Takes the Next Step in the Coronavirus Fight | 4/3/2020

ElectroCore shares absolutely exploded on Friday after the company announced an update for its COVID-19 treatment …

40 Stocks Moving In Friday’s Mid-Day Session | 4/3/2020

Gainers electroCore , Inc. (NASDAQ: ECOR ) shares climbed 44.3% to $1.0769 after the company announced it has submitted an Emergency Use Authorization application to the FDA to allow the study and use of gammaCore nvVNS therapy to treat respiratory symptoms associated with the coronavirus. Enel Americas S.A. (NYSE: ENIA ) climbed 16.8% to $6.76. Super League Gaming, Inc. (NASDAQ: SLGG ) gained 13.5% to $2.3501. PaySign, Inc. (NASDAQ: PAYS ) shares climbed 12.3% to …

Clinical Research

New Stimulating Device May Prevent Migraine | News, Sports, Jobs - Wheeling Intelligencer | 2/17/2020

… Feb 17, 2020 West Virginia University School of Medicine researcher Umer Najib is studying whether this neuromodulation device — made by electroCore — can prevent migraine in people who apply it to their necks three times a … or areas of the brain,” explained Najib, who directs the clinical research program for the School of Medicine’s Department of Neurology. In a new clinical trial he’s leading, neuromodulation takes the form of a cell …

Cell-phone-sized device that stimulates nerve in neck may prevent migraine - EurekAlert | 1/24/2020

WVU School of Medicine researcher Umer Najib is studying whether this neuromodulation device–made by electroCore–can prevent migraine in people who apply it to their necks three times a day. If… view more Credit … or areas of the brain,” explained Najib, who directs the clinical research program for the School of Medicine’s Department of Neurology. In a new clinical trial he’s leading, neuromodulation takes the form of a cell …

Clinical Data

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cadence Bancorp, Eldorado Resorts, Sundial Growers, and electroCore and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

… on behalf of stockholders of Cadence Bancorp (NYSE: CADE), Eldorado Resorts, Inc. (NASDAQ: ERI), Sundial Growers, Inc. (NASDAQ: SNDL), and electroCore, Inc. (NASDAQ: ECOR). Stockholders have until the deadlines below to petition the court to … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 11/14/2019

… file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired: a) electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR ) common stock pursuant and/or traceable to … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

Bioelectronic Medicine

electroCore Announces Third Quarter 2019 Financial Results | Globe Newswire | 11/13/2019

November 13, 2019 16:05 ET Source: electroCore, Inc. Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13, at 4:30pm ET BASKING RIDGE, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) – electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced third quarter 2019 financial results and provided an operational update. Third Quarter 2019 and Recent Highlights Net …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in electroCore, Inc. of Class Action Lawsuit and Upcoming Deadline – ECOR | Globe Newswire | 11/12/2019

November 11, 2019 18:22 announces that a class action lawsuit has been filed against electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR) and certain of its officers. The class action, filed in United States District … number, and the number of shares purchased. electroCore is a bioelectronic medicine company with a non-invasive vagus nerve stimulation (“VNS”) therapy. Its lead product gammaCore is used for the acute treatment of pain associated …

Food and Drug Administration

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN … on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN … on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use …

ACO

electroCore Announces Distribution Agreement with Doctor’s Medical LLC to Expand Patient Access to gammaCore | Globe Newswire | 8/12/2019

August 12, 2019 16:05 ET Source: electroCore, Inc. BASKING RIDGE, N.J., electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patients with workers’ compensation injuries and automobile personal injury claims. This agreement opens access to gammaCore for millions of workers who have been injured as part of a workers …

Multiple Abstracts Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) to be Presented at the American Headache Society’s 61st Annual Scientific Meeting | Globe Newswire | 7/10/2019

About electroCore, Inc. electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in … with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this …

Boston Scientific

Global Transcutaneous Electrical Nerve Stimulation Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025 | Globe Newswire | 4/1/2020

Boston Scientific Corporation, Medtronic plc, NeuroMetrix, Inc., Nevro Corp, Bioness,Inc., Cogentix Medical, Inc., electroCore, Inc., and Uroplasty, Inc.. On the basis of Surgery Procedures, the Global Transcutaneous Electrical Nerve Stimulation Market is studied across Direct Nerve Repair, Nerve Grafting, and Stem Cell Therapy. On the basis of Product, the Global Transcutaneous Electrical Nerve Stimulation Market is studied across Desktop and Portable. On the basis of End User, the Global …

Global Transcutaneous Electrical Nerve Stimulation Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025 | Globe Newswire | 4/1/2020

Boston Scientific Corporation, Medtronic plc, NeuroMetrix, Inc., Nevro Corp, Bioness,Inc., Cogentix Medical, Inc., electroCore, Inc., and Uroplasty, Inc.. On the basis of Surgery Procedures, the Global Transcutaneous Electrical Nerve Stimulation Market is studied across Direct Nerve Repair, Nerve Grafting, and Stem Cell Therapy. On the basis of Product, the Global Transcutaneous Electrical Nerve Stimulation Market is studied across Desktop and Portable. On the basis of End User, the Global …

LivaNova

Neuromodulation Devices Market to Hit USD 9.34 Billion by 2026; Increasing Patient Population Worldwide to Feed Market Expansion: Fortune Business Insights™ | 3/25/2020

Key Companies Profiled in the Neuromodulation Devices Market Research Report are NeuroPace, Inc., Neuronetics, Abbott, electroCore, Inc., LivaNova PLC, ReShape Lifesciences, Inc., Inspire Medical Systems, Inc., Boston Scientific Corporation, Medtronic and other key market players. March 25, 2020 07:52 ET Source: Fortune Business Insights Pune, The global neuromodulation devices market size is projected to reach USD 9.34 billion by 2026, exhibiting a CAGR of 9.5% during the forecast period. Steady …

Neuromodulation Devices Market to Hit USD 9.34 Billion by 2026; Increasing Patient Population Worldwide to Feed Market Expansion: Fortune Business Insights™ | 3/25/2020

Key Companies Profiled in the Neuromodulation Devices Market Research Report are NeuroPace, Inc., Neuronetics, Abbott, electroCore, Inc., LivaNova PLC, ReShape Lifesciences, Inc., Inspire Medical Systems, Inc., Boston Scientific Corporation, Medtronic and other key market players. Pune, March 25, 2020 (GLOBE NEWSWIRE) – The global neuromodulation devices market size is projected to reach USD 9.34 billion by 2026, exhibiting a CAGR of 9.5% during the forecast period. Steady climb in the prevalence …

Myriad Genetics

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sundial, electroCore, Tencent, and Myriad Genetics and Encourages Investors to Contact the Firm | Globe Newswire | 11/7/2019

00 ET Source: Bragar Eagel & Squire Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sundial Growers, Inc. (NASDAQ: SNDL), electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), and Myriad Genetics, Inc. (NASDAQ: MYGN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

October 30, 2019 17:00 ET Source: Bragar Eagel & Squire NEW YORK, Oct. 30, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), and Waitr Holdings, Inc. (NASDAQ: WTRH). Stockholders have until the deadlines below to petition the …

GeneSight

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sundial, electroCore, Tencent, and Myriad Genetics and Encourages Investors to Contact the Firm | Globe Newswire | 11/7/2019

… firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sundial Growers, Inc. (NASDAQ: SNDL), electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), and Myriad Genetics, Inc. (NASDAQ … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Merck

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

electroCore Completes $70 Million Series B Funding Round Investment to fund commercialization of gammaCore® and further clinical development of nVNS News provided by 08:45 ET Share this article BASKING RIDGE, N.J. , Nov. electroCore, a U.S … financing also included significant participation from another Series A investor, Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of …

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

BASKING RIDGE, N.J. , Nov. electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced today it completed its Series B financing that has brought in just over … financing also included significant participation from another Series A investor, Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of …

Merck & Co

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

electroCore Completes $70 Million Series B Funding Round Investment to fund commercialization of gammaCore® and further clinical development of nVNS News provided by 08:45 ET Share this article BASKING RIDGE, N.J. , Nov. electroCore, a U.S … Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of Knoll Capital Management, as well as American Investment Holdings LLC …

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

BASKING RIDGE, N.J. , Nov. electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced today it completed its Series B financing that has brought in just over … Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of Knoll Capital Management, as well as American Investment Holdings LLC …

Zacks Investment Research

electroCore (NASDAQ:ECOR) Upgraded to “Buy” at Zacks Investment Research - Dakota Financial News | 2/3/2020

Zacks Investment Research upgraded shares of electroCore (NASDAQ:ECOR) from a hold rating to a buy rating in a report released on Thursday morning, Zacks.com reports. They currently have $1.50 target price on the stock. According to Zacks, “Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. “ ECOR has been the …

electroCore (NASDAQ:ECOR) Raised to “Buy” at Zacks Investment Research - TheOlympiaReport | 2/2/2020

Zacks Investment Research upgraded shares of electroCore (NASDAQ:ECOR) from a hold rating to a buy rating in a research report report published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $1.50 price objective on the stock. According to Zacks, “Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States …

Merck Global Health Innovation

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

electroCore Completes $70 Million Series B Funding Round Investment to fund commercialization of gammaCore® and further clinical development of nVNS News provided by 08:45 ET Share this article BASKING RIDGE, N.J. , Nov. electroCore, a U.S … or on the order of a licensed healthcare provider. About Merck Global Health Innovation Fund With a vision that data will be the currency in healthcare, Merck GHI is building a carefully integrated portfolio of …

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

BASKING RIDGE, N.J. , Nov. electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced today it completed its Series B financing that has brought in just over … or on the order of a licensed healthcare provider. About Merck Global Health Innovation Fund With a vision that data will be the currency in healthcare, Merck GHI is building a carefully integrated portfolio of …

Merck Global Health Innovation Fund

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

electroCore Completes $70 Million Series B Funding Round Investment to fund commercialization of gammaCore® and further clinical development of nVNS News provided by 08:45 ET Share this article BASKING RIDGE, N.J. , Nov. electroCore, a U.S … or on the order of a licensed healthcare provider. About Merck Global Health Innovation Fund With a vision that data will be the currency in healthcare, Merck GHI is building a carefully integrated portfolio of …

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

BASKING RIDGE, N.J. , Nov. electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced today it completed its Series B financing that has brought in just over … or on the order of a licensed healthcare provider. About Merck Global Health Innovation Fund With a vision that data will be the currency in healthcare, Merck GHI is building a carefully integrated portfolio of …

Innovation Fund

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

electroCore Completes $70 Million Series B Funding Round Investment to fund commercialization of gammaCore® and further clinical development of nVNS News provided by 08:45 ET Share this article BASKING RIDGE, N.J. , Nov. electroCore, a U.S … significant participation from another Series A investor, Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of Knoll Capital Management …

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

BASKING RIDGE, N.J. , Nov. electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced today it completed its Series B financing that has brought in just over … significant participation from another Series A investor, Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of Knoll Capital Management …

Health Innovation Fund

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

electroCore Completes $70 Million Series B Funding Round Investment to fund commercialization of gammaCore® and further clinical development of nVNS News provided by 08:45 ET Share this article BASKING RIDGE, N.J. , Nov. electroCore, a U.S … included significant participation from another Series A investor, Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of Knoll Capital …

electroCore Completes $70 Million Series B Funding Round | PR Newswire | 11/29/2017

BASKING RIDGE, N.J. , Nov. electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced today it completed its Series B financing that has brought in just over … included significant participation from another Series A investor, Merck’s Global Health Innovation Fund, a venture capital arm of Merck & Co. Inc. Investors participating in recent Series B closings included Gakasa, an affiliate of Knoll Capital …

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 11/14/2019

November 14, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Law Offices of Howard G. Smith reminds investors of the upcoming November 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired: a) electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR ) common stock pursuant and/or traceable to the registration statement and prospectus …

Bragar Eagel

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cadence Bancorp, Eldorado Resorts, Sundial Growers, and electroCore and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

November 13, 2019 18:18 ET Source: Bragar Eagel & Squire NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Cadence Bancorp (NYSE: CADE), Eldorado Resorts, Inc. (NASDAQ: ERI), Sundial Growers, Inc. (NASDAQ: SNDL), and electroCore, Inc. (NASDAQ: ECOR). Stockholders have until the deadlines below to petition the court to …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 11/8/2019

… the upcoming November 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR ) investors who acquired common stock pursuant and … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . In June 2018, electroCore

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in electroCore, Inc. of Class Action Lawsuit and Upcoming Deadline – ECOR | Globe Newswire | 11/6/2019

… LLP NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) – Pomerantz LLP announces that a class action lawsuit has been filed against electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR) and certain of its officers. The class … can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include …

Abraham L. Pomerantz

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of electroCore, Inc. – ECOR | Globe Newswire | 10/24/2019

… Source: Pomerantz LLP NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) – Pomerantz LLP is investigating claims on behalf of investors of electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR). Such investors are advised to contact Robert … corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than …

Peretz Bronstein

SHAREHOLDER ALERT - electroCore, Inc. (ECOR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: November 25, 2019 | Globe Newswire | 10/11/2019

… LLC NEW YORK, Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR) and certain of its officers, on behalf … visit the firm’s site: www.bgandg.com/ecor or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in electroCore you …

Yael Hurwitz

SHAREHOLDER ALERT - electroCore, Inc. (ECOR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: November 25, 2019 | Globe Newswire | 10/11/2019

… LLC NEW YORK, Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR) and certain of its officers, on behalf … may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in electroCore you have until November 25, 2019 to request that …

Phillip Kim

ECOR LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against electroCore, Inc. - ECOR | Business Wire | 9/28/2019

… investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of electroCore, Inc. (NASDAQ: ECOR) (a) pursuant and/or traceable to the registration statement and prospectus … go to http://www.rosenlegal.com/cases-register-1605.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN …

Laurence Rosen

ECOR LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against electroCore, Inc. - ECOR | Business Wire | 9/28/2019

… investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of electroCore, Inc. (NASDAQ: ECOR) (a) pursuant and/or traceable to the registration statement and prospectus … has secured hundreds of millions of dollars for investors. Contacts Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free …

Brian Schall

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against electroCore, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Business Wire | 9/27/2019

… ANGELES- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against electroCore, Inc. (“electroCore” or “the Company”) (NASDAQ: ECOR ) for violations of §§10(b) and 20 … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

Joseph E. Levi

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of electroCore, Inc. | Globe Newswire | 9/23/2019

September 23, 2019 10:12 23, Levi & Korsinsky notifies investors that it has commenced an investigation of electroCore, Inc. (“electroCore” or “the Company”) (NASDAQ: ECOR) concerning possible violations of federal securities laws. On June 22, 2018 … https://www.zlk.com/pslra-1/electrocore-inc-loss-form or contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500. Levi California, Connecticut firm’s in prosecuting securities litigation involving financial fraud …

Jeff Vinik

Jeff Vinik backs emerging therapy for migraine and cluster headaches | 12/5/2017

TAMPA — With ventures in pro sports and real estate development , Tampa Bay Lightning owner Jeff Vinik remains one of the bay area’s busiest business executives, and his money seems to be working on even more fronts. A New Jersey-based bioelectronic medicine company, electroCore, has announced that two groups associated with Vinik — American Investment Holdings and the Vinik Family Foundation — were among the investors that participated in …